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Brandon David Downing 
MYELOID CELLS INDUCE NEUROFIBROMATOSIS TYPE 1 ANEURYSM 
FORMATION THROUGH INFLAMMATION AND OXIDATIVE STRESS 
Neurofibromatosis Type 1 (NF1) is a genetic disorder resulting from 
mutations in the NF1 tumor suppressor gene. Neurofibromin is the protein 
product of NF1 and functions as a negative regulator of Ras activity in both 
hematopoietic and vascular wall cells, which are critical for maintaining blood 
vessel homeostasis. NF1 patients are predisposed to chronic inflammation and 
premature cardiovascular disease, including development of large arterial 
aneurysms, which may result in sudden death secondary to their rupture. 
However, the molecular pathogenesis of NF1 aneurysm formation is completely 
unknown. Utilizing a novel model of Nf1 murine aneurysm formation, we 
demonstrate that heterozygous inactivation of Nf1 (Nf1+/-) results in enhanced 
aneurysm formation with myeloid cell infiltration and increased reactive oxygen 
species in the vessel wall. Using cell lineage-restricted transgenic mice, we show 
that loss of a single Nf1 allele in myeloid cells is sufficient to recapitulate the 
Nf1+/- aneurysm phenotype in vivo. Additionally, oral administration of 
simvastatin, a statin with antioxidant and anti-inflammatory effects, significantly 
reduced aneurysm formation in Nf1+/- mice. Finally, the antioxidant apocynin was 
administered orally and also resulted in a significant reduction of Nf1+/- 
aneurysms. These data provide genetic and pharmacologic evidence that 
neurofibromin-deficient myeloid cells are the central cellular triggers for 
aneurysm formation in a novel model of NF1 vascular disease, implicated 
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oxidative stress as the key biochemical mechanisms of NF1 aneurysm formation 
and provide a potential therapeutic target for NF1 vasculopathy. 
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CHAPTER ONE 
DEVELOPMENT OF TWO NOVEL NF1 HETEROZYGOUS ANEURYSM 
MODELS AND IDENTIFICATION OF MYELIOD CELLS AS THE PRIMARY 
EFFECTORS OF NF1+/- ANEURYSM FORMATION 
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INTRODUCTION 
 
Neurofibromatosis Type 1. 
Neurofibromatosis Type 1 (NF1) is a common autosomal dominant 
genetic disorder affecting 1 in 3,000 live births resulting from mutations in the 
NF1 tumor suppressor gene (1, 2). The NF1 gene is located on chromosome 17 
at position 17q11.2 (3) spanning over 350 kilobases accounting for 60 exons 
encoding the protein neurofibromin (4). Neurofibromin negatively regulates p21ras 
(Ras) activity via stimulation of its GTPase function (1, 5, 6). Mutations in NF1 
can be inherited; however, 30 to 50% of NF1 cases result from de novo 
mutations (7-9). Over 240 mutations have been described which cause NF1 (10) 
including deletions, duplications, frame shift mutations, insertions, nonsense 
mutations and substitutions (11). Mutations causing NF1 affect only one allele of 
the NF1 gene although loss of heterozygosity (LOH) has been described in 
primary tumor samples from NF1 patients (12, 13). The clinical diagnosis of NF1 
is made based on recommendations by the National Institutes of Health (NIH) 
where two of the seven following clinical findings are present: 1) six or more café-
au-lait macules (5 mm or more pre-pubertal or 15 mm or more post-pubertal) 2) 
two or more neurofibromas or one plexiform neurofibroma 3) freckling in the 
axillary or inguinal regions 4) optic glioma 5) two or more Lisch nodules 6) bone 
lesions including sphenoid dysplasia or thinning of long bone cortex 7) a first 
degree relative with NF1 (14, 15). Therefore, haploinsufficiency of NF1 causes 
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disease with complete penetrance (9) and a variety of clinical manifestations in 
several organ systems (7, 8). 
Common non-neoplastic manifestations of NF1 can affect the 
integumentary, skeletal, nervous and cardiovascular systems characterized by 
café-au-lait spots, bone dysplasia, cutaneous neurofibromas and aneurysmal 
disease, respectively (16). Additionally, LOH can lead to neoplasms in the 
hematopoietic, gastrointestinal, and central nervous systems (16, 17). Previous 
studies have found decreased neurofibromin levels lead to phenotypic cellular 
changes such as increased proliferation and migration and decreased apoptosis 
in endothelial cells (18), fibroblasts (19), vascular smooth muscle cells (20), mast 
cells (21) and macrophages (22). Overall, NF1 is common genetic disease that 
affects many different cell types and tissues and results in a spectrum of clinical 
findings and severities. 
 
Neurofibromatosis Type 1 and Cardiovascular Disease. 
Cardiovascular disease (CVD) is a serious but under-recognized 
complication of NF1 (23). NF1 patients with CVD display a wide range of lesions, 
affecting both arteries and veins, contributing to increased morbidity and mortality 
(24-26). Specifically, aneurysms or stenosis of the aortic, renal, and mesenteric 
arteries are the most common lesions (25). Most lesions occur by 50 years of 
age and are secondary to an underlying vasculopathy (23, 25). Importantly, these 
vascular lesions can progress over time or recur following treatment (27-29). 
Lesions affecting the renal arteries are the most common vascular abnormalities 
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identified in NF1 patients affecting up to 5% of patients (23). Patients may 
present with hypertension due to improper renovascular regulation of blood 
pressure secondary to intimal hyperplasia or renal vascular wall remodeling due 
to aneurysm formation (30). Renovasular hypertension usually presents by early 
adulthood and has been recognized during pregnancy as eclampsia or 
gestational hypertension (31, 32). Although renal lesions may present with 
hypertension, many vascular lesions located throughout the rest of the body may 
only be evident during unrelated imaging studies or at the time of a catastrophic 
vascular event. Though the frequency of NF1 vasculopathy is difficult to define 
due to a lack of routine screening and asymptotic nature of many lesions (33), 
the prevalence of vascular lesions in large clinical series ranges between 2.0% to 
6.4% (25, 26, 29).  
Studies utilizing genetic mouse models which recapitulate NF1 
vasocclusive disease reveal that heterozygous inactivation of Nf1 (Nf1+/-) in bone 
marrow derived cells contributes to neointima hyperplasia and vessel lumen 
stenosis after arterial injury (22, 34, 35). Clinical studies demonstrate that NF1 
patients have evidence of chronic inflammation and mobilization of a specific pro-
inflammatory monocyte subset, characterized as CD14dimCD16hi, in their 
peripheral blood that has been linked to the development of vasocclusive disease 
and aneurysm formation in non-NF1 patients with CVD (22, 36, 37). Additionally, 
it was noted that in Nf1+/- mice the murine equivalent of CD14dimCD16hi 
monocytes characterized by the Ly6Chi membrane marker was increased in non-
challenged 12-week old male mice (20). When both copies of Nf1 were ablated in 
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myeloid cells alone the number of Ly6Chi monocytes increased further indicting a 
connection between neurofibromin insufficiency within myeloid cells and vascular 
inflammation (20). Despite these observations from clinical and murine studies, 
the pathogenesis of NF1 aneurysm disease is completely unknown partly due to 
a lack of animal models that mimic the human vascular disease. Given the 
mostly silent presentation of aneurysms in NF1 patients and the potential for 
catastrophic rupture of these lesions, understanding disease pathogenesis is 
critical for their prevention, early detection and treatment. Therefore, the specific 
aims addressed within this project include: 
1. Development of a tractable murine model of Nf1 heterozygous 
aneurysm formation. 
2. Identification of the cellular mechanism leading to Nf1 heterozygous 
aneurysm formation utilizing lineage-restricted transgenic mice. 
3. Identification of biochemical processes leading to Nf1 heterozygous 
aneurysm formation utilizing pharmacologic inhibition studies. 
 
Neurofibromin. 
 Neurofibromin, encoded by the NF1 tumor suppressor gene, is a GTPase 
activating protein (GAP) and functions as a negative regulator of Ras. 
Neurofibromin accelerates intrinsic GTPase activity of Ras leading to the 
hydrolysis of active Ras-GTP to its inactive Ras-GDP form (5, 6, 38). 
Neurofibromin has been shown to be expressed in many of the cells important for 
vessel homeostasis including vascular smooth muscle cells (VSMCs), endothelial 
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cells (39), myeloid cells (40) and fibroblasts (41) as well as cells associated with 
the central and peripheral nervous system including neurons, Schwann cells and 
oligodendrocytes (42). Additionally, studies have shown that at least one copy of 
functional Nf1 is necessary for development. Developing embryos with 
homozygous deletion of Nf1 die at embryonic day 13.5 and display cardiac 
malformations (43). Mice with heterozygous deletion of Nf1 develop normally and 
do not display cardiac malformation or external phenotypic differences from their 
WT littermates although extended studies reveal that some Nf1+/- mice develop 
tumors and leukemia similar to those seen in NF1 patients (44). 
 
Aneurysm Pathogenesis. 
 Abdominal aortic aneurysms (AAA) affect up 9% of adults 65 years and 
older (45, 46) with 15,000 patients dying each year in the United States from 
ruptured or dissected AAAs (47). Risk factors associated with AAA formation 
include smoking, male gender, advanced age, Caucasian race, atherosclerosis, 
hyperlipidemia, hypertension and family history of AAA (48). Additionally, several 
single gene disorders affecting the connective tissue of the vascular wall 
predispose younger patients to aneurysms of the aorta from the aortic root to the 
iliac bifurcation including Ehlers-Danlos syndrome, Loeys-Dietz syndrome, 
Marfan System, Turner syndrome and Familial thoracic aortic aneurysm and 
dissection (49). These genetic disorders indicate that connective tissue 
maintenance in the vascular wall is an important aspect of maintaining vascular 
homeostasis and withstanding the hemodynamic forces within the aorta. Matrix 
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metalloproteinases (MMPs), a family of proteases that possess the ability to 
degrade most extracellular matrix (ECM) components in the vascular wall, have 
been found to be more prevalent in AAA tissue than normal aortic tissue (50, 51). 
MMPs are secreted from many cells types within the vessel wall as inactive 
zymogen precursors and require extracellular activation to expose the protease 
active site (51). Specifically, pro-MMP-2 and pro-MMP-9, which degrade elastin, 
are secreted by VMSCs and macrophages, respectively (50, 52, 53). Activation 
of pro-MMPs can occur through many mechanisms including inflammation (54), 
oxidative stress (55), and other proteases such as plasmin (56). The active forms 
of both MMP-2 and MMP-9 have been found in higher concentrations within 
aneurysmal aortic tissue compared to normal aortic tissue (57). Importantly, 
Longo et al. (58) investigated the role of both MMP-2 and MMP-9 in aneurysm 
formation and found that complete genetic ablation of either protease inhibited 
aortic dilation. However, when WT macrophages were infused and challenged, 
only the MMP-9 knockout mice formed aneurysms, suggesting that MMP-2 from 
the vessel wall and MMP-9 from macrophages work in concert to induce 
aneurysms. Doxycyclin, a non-selective inhibitor of several MMPs has also been 
shown to efficiently inhibit aneurysm formation (59).  
 Besides matrix degradation, other hallmarks of aneurysm pathogenesis 
include oxidative stress and inflammation (60-62). Studies in animal models 
using angiotensin II (Ang II) have shown that chronic infusion of Ang II will induce 
AAA formation while showing an increase in oxidative stress, inflammation and 
matrix degradation within the aneurysmal tissue (63). Studies inducing AAAs with 
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Ang II have found that genetic or pharmacologic disruption of these biochemical 
processes can be protective. Specifically, Thomas et al. (64) showed that 
deletion of the p47phox subunit of the superoxide producing nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase complex (Nox) attenuated Ang II 
induced aneurysm formation in apolipoprotein E-deficient (ApoE-/-) mice. Several 
antioxidant agents have shown the ability to inhibit aneurysm formation in both 
murine (65) and rat (66) models of aneurysm formation although antioxidant 
treatments have not translated well to the human disease state. Finally, 
inflammatory cell recruitment and infiltration of the aortic media and adventia has 
been observed in both human and murine diseased tissue. Specifically, 
monocytes are attracted to the cell wall by ECM degradation products (67), 
granulocyte macrophage colony-stimulating factor (68), monocyte 
chemoattractant protein-1 (MCP-1) (69), and RANTES (regulated on activation, 
normal T cell expressed and secreted) (70). VSMCs simulated with the 
inflammatory mediators Ang II or tumor necrosis factor-alpha secrete MCP-1 
indicated a progression in which simulation of VSMCs causes release of MCP-1 
and subsequent monocyte attraction (71, 72). Overall, examination of human 
aneurysmal tissue and murine genetic and pharmacologic studies indicate that 
the primary biologic processes driving aneurysm formation are the VMSC 
chemokine-driven recruitment of monocytes to areas of vascular inflammation, 
differentiation of those monocytes to macrophages, and subsequent damage to 
the wall by release and activation of MMPs. 
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Murine Models of Aneurysm Formation. 
 Aneurysmal disease was initially studied by procurement of aneurysmal 
tissue from patients during aneurysm repair and performing IHC analysis to 
identify structural changes and cellular makeup of aneurysmal tissue compared 
to normal aortic tissue. These studies yielded a very limited view about how 
aneurysms developed and progressed. More recently aneurysm initiation and 
progression has been studied through the development of genetic and 
pharmacologically induced aneurysm models. Two genetic models of impaired 
ECM development and maintenance have been studied. First, the blotchy mouse 
contains a mutation of the ATP7A gene, which encodes a copper-transporting 
ATPase that leads to a copper deficiency (73). Lysyl oxidase is involved in the 
cross linking of collagen and elastin fibers for which copper is a co-factor (74), 
therefore defects in the ECM matrix predispose these mice as well as Menkes’ 
disease patients with the equivalent mutations, to aneurysm formation. 
Alternatively, genetically engineered mice deficient in TIMP-1 (tissue inactivator 
of metalloproteinases-1) show increased aneurysm formation due to increased 
activated MMPs breaking down the vascular wall ECM (75, 76). These models 
illustrate the importance of proper ECM formation and maintenance to aneurysm 
progression, but fail to address which factors translate from environmental risk to 
ECM breakdown and aneurysm formation.  
 Hyperlipidemic mice have been an important model for the induction and 
analysis of aneurysm formation by employing a well-established risk factor for 
aneurysm induction. Mice fed a high fat diet alone will develop atherosclerosis 
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and aneurysms over time. More recently, mice deficient in low-density lipoprotein 
receptor (LDLr) (77) or ApoE (78, 79) have been developed and allow for 
increased aneurysm formation when on a high fat diet for up to one year (80). 
ApoE-/- mice on a high fat diet formed aneurysms in the aorta near and under 
areas of atherosclerosis (80). The observation of aneurysm formation near 
atherosclerotic plaques containing foam cell macrophages indicates that 
inflammation and MMP release from macrophages may be the link between ECM 
degradation and the hyperlipidemic risk factor and ECM degradation (81). 
Additionally, this model indicates macrophage recruitment to the vascular wall 
may be an important early process in aneurysm formation. 
 Chemically-induced aneurysm formation represents the majority of current 
models being used for the investigation of aneurysm development and 
progression due to reduced amount of time required for induction. Elastase 
infusion into the infrarenal aorta has been used extensively and allows for 
aneurysm formation in 14 to 21 days (82). Elastase infusion leads to aneurysm 
formation by breaking down the elastin portion of the ECM in the infused 
segment. Due to the short time period of this model the progression of aneurysm 
formation can be reliable tracked. The limitation of this model is similar to the 
limitation of the genetic mouse models with ECM deficiency, the infusion itself 
breaks down the ECM rather than the vascular wall cells or recruited cells which 
likely do this during inflammation, repair and resolution. 
 Finally, Ang II infusion (500 to 1000 ng/kg/min) over 28 days via a 
subcutaneous osmotic mini-pump induces aneurysm formation in LDLr-/- and 
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ApoE-/- mice in the suprarenal aorta (63). Interestingly, Ang II at these doses only 
slightly increased blood pressure (83, 84). During subsequent studies, MMP 
inhibition prevented aneurysm formation (85) precluding blood pressure from 
being the sole mechanism of aneurysm formation in the Ang II infusion model. 
Ang II infusion has allowed for temporal characterization of the events leading to 
aneurysm formation (86). Macrophages accumulate within the first few days of 
infusion in the suprarenal aorta and are associated with elastin degradation. It is 
likely that Ang II stimulation of VSMCs results in the release of MCP-1 and MMP-
2, which subsequently produces ECM degradation products. Both MCP-1 and 
the ECM degradation products attract monocytes to the stimulated site of the 
suprarenal aorta (87). Aneurysm formation has also been induced with Ang II 
infusion in WT C57B/6 mice allowing for a wild-type genetic background to be 
used. Aneurysms formed in WT mice were comparable in size to hyperlipidemic 
mice but occurred less frequently (88). Taken together, of the previous aneurysm 
studies utilizing various models of murine aneurysm induction, Ang II is very 
tractable model due to its limited time to induce aneurysms as well as its 
mechanism in which VSMCs are stimulated leading to inflammatory cell 
recruitment. 
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MATERIALS AND METHODS 
 
Animals. 
All protocols were approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee. Nf1+/– mice were obtained from 
Tyler Jacks (Massachusetts Institute of Technology, Cambridge) and 
backcrossed 13 generations into the C57BL/6J strain. Nf1fl/fl mice were obtained 
from Luis Parada (University of Texas Southwestern Medical Center, Dallas) and 
backcrossed 13 generations into the 129SvJ strain. Lysozyme cre (LysMcre, stock 
4781) and smooth muscle protein-22α cre (SM22cre, stock 4746) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained on 
C57BL/6 strain. Nf1fl/fl mice were inter-crossed with LysMcre or SM22cre mice to 
generate F1 C57BL/6 × 129SvJ progeny. Specifically, Nf1fl/+;LysMcre, 
heterozygous loss of Nf1 in myeloid cells only, and Nf1fl/+;SM22cre, heterozygous 
loss of Nf1 in vascular smooth muscle cells (VSMCs) only, mice were used for 
experiments. Cre-mediated recombination was confirmed by PCR as previously 
described (89). LacZ lineage tracing of aortas from Nf1fl/+;Rosa26fl/+;Sm22cre mice 
revealed deep staining limited to the media of the vessel wall where VSMCs 
reside. LacZ lineage tracing of aortas from Nf1fl/+;Rosa26fl/+;LysMcre mice 
revealed very sparse staining limited to the vessel adventitia, a common area for 
limited numbers of macrophages under physiological conditions. Nf1+/- 129SvJ 
mice inter-crossed with Nf1+/– C57BL/6 mice generated F1 Nf1+/– and wild type 
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(WT) controls animals for experiments. All genotyping was performed according 
to Jackson Laboratory protocols or as previously described (89, 90). 
 
Angiotensin II Infusion Abdominal Aortic Aneurysm Model. 
12 week-old WT and Nf1+/- male mice were infused with Angiotensin II 
(Ang II, 1500 ng/kg/min, Calbiochem, CA) or saline as previously described (91), 
with modification. In brief, animals were anesthetized by inhalation of an 
isoflurane (2%)/oxygen (98%) mixture, and an Alzet osmotic minipump (2006, 
Durect Corporation, CA) containing Ang II or saline was implanted into a 
subcutaneous pocket through an incision of the skin on the rear flank. The 
incision was closed using 5-0 prolene suture (Advanced Inventory Management). 
The incision site healed rapidly with no sign of infection. At indicated time points, 
the arterial tree was perfused at a constant physiologic pressure (100 mmHg) 
with 0.9% sodium chloride. Under a dissecting scope (Leica), a portion of the 
arterial tree was excised en bloc including carotid, aortic, iliac and femoral 
arteries after removal of adventitial fat. Some vessels were fixed with Zinc-
formalin solution (1x, Anatech) before paraffin embedding. 
 
Classification and Quantification of Abdominal Aortic Aneurysms. 
Digital images of harvested arteries were obtained with a Nikon camera on 
a Zeiss stereo-microscope (Carl Zeiss Inc) or a Nikon digital camera. The 
maximum external arterial diameters were measured using Metamorph 6.1 
(Universal Imaging Systems Corp.) by a single observer blinded to the infusion 
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and/or treatment and genotype of the mice. Aneurysms were defined as an 
increase in the external aortic diameter of >/= 50% as compared to control 
animals. Aortic aneurysm severity was rated from Type 0 to Type IV according to 
the method of Martin-McNulty et al. (92) with modification: Type 0, no aneurysm; 
Type I, discernable dilation 1.5 to 2 times the diameter of a normal corresponding 
artery; Type II, a single dilation that is more than 2 times the diameter of a normal 
corresponding artery; Type III, multiple dilations along the harvested vasculature 
with the largest dilation being 1.5 to 2 times the diameter of a normal 
corresponding artery; and Type IV, multiple dilations along the harvested 
vasculature with the largest dilation being more than 2 times the diameter of a 
normal corresponding artery. 
 
Histopathology and Immunohistochemistry. 
Aortas were either paraffin or optimum cutting temperature (OCT) 
embedded and serial 5 µm cross-sections were made through the length of the 
aorta at its largest diameter. Paraffin sections were stained with H&E (Anatech), 
Verhoeff's van Gieson (Sigma) for elastic lamina, Masson's trichrome (Sigma) for 
collagen, and Toluidine blue (Anatech) for mast cells. Elastic lamina preservation 
was graded as follows: grade 1, intact elastic lamina; grade 2, elastic lamina with 
some interruptions; and grade 3, severe elastin fragmentation. For 
immunohistochemistry, paraffin or OCT-embedded sections were de-waxed or 
acetone fixed, respectively, followed by low pH citrate antigen retrieval 
(DakoCytomation target retrieval solution citrate pH 6; Dako). Sections were 
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Protein Blocked (Dako) and incubated separately with anti-CD3 (1:100, BD 
Pharmingen), anti-B220 (1:100, BD Pharmingen), anti-alpha smooth muscle actin 
(α-SMA, 1:200, Abcam), anti-Mac-3 (1:50, BD Pharmingen), anti-matrix 
metalloproteinase-2 (MMP2, 1:2000, Abcam) and anti-matrix metalloproteinase-9 
(MMP9, 1:1000, Abcam) primary antibodies. Sections were incubated with the 
appropriate fluorescent secondary antibody (Alexa Flour 647 goat anti-rat IgG or 
Alexa Flour 488 goat anti-rat, life technologies) and visualized with fluorescent 
microscopy (Leica) or biotinylated secondary antibody (Vector Laboratories) 
followed by incubation with the ABC kit (Vector Lab), and visualized by 3,3’-
diaminobenzidine (DAB; Vector Laboratories) and counterstained with 
hematoxylin. The average number of CD3+, B220+, F4/80+, Mac-3+ and mast 
cells were calculated from five independent high power fields (HPF) from five 
sections at 50µm intervals. Some OCT embedded cross-sections were co-
stained with fluorescent α-SMA and anti-Mac-3 with Alexa Flour 488 goat anti-rat 
secondary. 
 
Murine Blood Pressure Measurements. 
Blood pressure measurements were obtained as previously described (93), 
with modification. Mice were anesthetized with an isoflurane (2%)/oxygen (98%) 
mixture and placed on a heating block in a supine position. The femoral artery 
was exposed under a dissecting microscope (Leica). A heat-stretched 
polyethylene (PE)-50 tube (BD Biosciences) was inserted into the femoral artery. 
During the reading, the arterial line was connected to a pressure transducer (AD 
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Instruments, Colorado Springs, CO) and signal was acquired on a Blood 
Pressure Display Unit (StemTech, Milwaukee, WI), transmitting to a DI-205 
signal interface (DATAQ Instruments, Akron, OH). Blood pressure readings were 
recorded with WinDAQ Version 2.15 software (DATAQ Instruments, Akron, OH). 
Blood pressure was recorded for three minutes with mean pressure reported. 
 
Matrix Metalloproteinase Activity Analysis. 
To detect MMP activity in abdominal aortas, in situ zymography and 
gelatin zymography were performed as previously described (94). Briefly, for in 
situ zymography, fresh frozen, OCT-embedded aortic sections (10 µm) from 18-
day saline or Ang II infused WT and Nf1+/- mice were incubated with a dye-
quenched gelatin substrate (DQ gelatin, Molecular Probes) according to the 
manufacturer’s protocol. After cleavage of DQ-gelatin by gelatinolytic activity in 
the tissue, green fluorescence was photographed by fluorescence microscopy 
(Leica). Addition of EDTA (20 mM) in gelatin substrate before incubation was 
used to assess the specificity of MMP activity. For gelatin zymography, 10 µg of 
homogenates lysed from fresh frozen segments of aorta from 18-day saline or 
Ang II infused WT and Nf1+/- mice in lysis buffer (50 mm Tris-HCl (pH 7.4), 0.2 m 
NaCl, and 10 mm CaCl2) were electrophoresed in a 10% SDS-polyacrylamide 
gel containing 1 mg/mL gelatin (Invitrogen). Gels were incubated for 36 hours 
(37°C) in zymography buffer (50 mmol Tris (pH 8.0), 10 mmol CaCl2, 0.05% Brij 
35, 0.02% NaN3) and stained with Coomassie brilliant blue followed by 
destaining to visualize clear bands, indicating active proteinase. 
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In situ Superoxide Detection. 
To detect ROS generation in abdominal aortas, in situ dihydroethidium 
(DHE) staining was performed as previously described (95). OCT embedded 
cross-sections (10 µm) of abdominal aortas were incubated with DHE (5 µM) 
(Molecular Probes Inc.) for 30 minutes at 37°C, rinsed with phosphate buffered 
saline (PBS), and mounted with ProLong Gold Antifade Reagent (Invitrogen), 
and photographed using fluorescent microscopy. 
 
Statistical Analysis. 
Quantitative results are shown as mean ± standard error of the mean (SEM). 
All statistical analyses were performed using the Prism 5 (GraphPad Software). P 
values were obtained by the unpaired Student’s t-test when comparison was 
between 2 groups, and by one-way analysis of variance (ANOVA) followed by a 
post hoc analysis using the Tukey’s test when comparison was made among 3 or 
more groups. To determine significance of distribution data was subjected to 
Fisher’s Exact test was used with Bonferroni correction. P values less than 0.05 
were considered significant. 
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RESULTS 
 
Heterozygous inactivation of Nf1 amplifies the incidence and severity of 
aneurysm formation within ApoE -/- mice. 
 ApoE-/- mice are predisposed to aneurysm formation when fed an 
atherogenic diet. Intercrossing genetically engineered mice with ApoE-/- mice is a 
standard model to study genetic contributions to aneurysm formation in 
experimental progeny (96). To test the hypothesis that Nf1 heterozygosity 
enhances aneurysm formation in vivo, ApoE-/- and ApoE-/-;Nf1+/- mice along with 
experimental controls (WT and Nf1+/- mice) were fed an atherogenic or normal 
chow diet for four months. Both ApoE-/- and ApoE-/-;Nf1+/- mice fed an 
atherogenic diet developed severe hypercholesterolemia and advanced 
atherosclerosis compared to mice fed normal chow (Table 1). WT and Nf1+/- mice 
fed a normal chow or atherogenic diet did not develop hypercholesterolemia or 
atherosclerosis. Heterozygosity of Nf1 in ApoE-/- mice did not alter cholesterol, 
triglyceride or glucose levels compared to ApoE-/- mice, and no difference in body 
weight or atherosclerotic lesion size between the two experimental groups was 
noted (Table 1). However, gross inspection of the aorta and its branches from 
ApoE-/-;Nf1+/- and ApoE-/- mice fed an atherogenic diet revealed an increased 
incidence of aneurysm formation in ApoE-/-;Nf1+/- when compared to control mice 
(Figure 1A). Neither ApoE-/- nor ApoE-/-;Nf1+/- mice fed normal chow developed 
aneurysms (Figure 1A).  
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 Quantification of the incidence and numbers of aneurysms in experimental 
mice fed an atherogenic diet revealed that 100 percent of ApoE-/-;Nf1+/- mice 
developed aneurysms compared to 40 percent of ApoE-/- mice, with a 16-fold 
increase in total number of aneurysms per animal (Figure 1B and 1C). The 
aneurysms were more severe in ApoE-/-;Nf1+/- mice as measured by a validated 
rating scale (Figure 1D) (92). These data indicate that heterozygous inactivation 
of Nf1 augments aneurysm formation in ApoE-/- mice. 
 NF1 patients and Nf1+/- mice have evidence of vascular inflammation with 
mobilization of discrete populations of inflammatory monocytes linked to 
aneurysm formation (22, 34). Therefore, we characterized the cellular 
architecture and structural composition of aneurysms in atherogenic diet fed 
ApoE-/- and ApoE-/-;Nf1+/- mice. Consistent with larger aneurysms, histologic 
examination of aneurysmal tissue from ApoE-/-;Nf1+/- mice displayed enhanced 
disruption of medial architecture, arterial diation, infiltration of inflammatory cells, 
and increased adventitial expansion compared to ApoE-/- mice fed an 
atherogenic diet (Figure 2A, 2B, and D). Trichrome staining identified enhanced 
collagen accumulation in the media and adventitia of ApoE-/-;Nf1+/- mice 
compared to ApoE-/- mice (Figure 2C), which is a hallmark of aneurysm formation 
(97).  
 Immunohistochemical (IHC) analysis of arterial cross-sections to identify 
the lineage of infiltrating immune cells populating the aneurysms revealed 
increased numbers of macrophages in both ApoE-/-;Nf1+/- and ApoE-/- mice fed an 
atherogenic diet (Figure 2D). Strikingly, the number of macrophages were 
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increased nearly 4-fold in ApoE-/-;Nf1+/- aortic cross-sections compared to ApoE-/- 
mice (ApoE-/-: 45.9 ± 3.3, n=7 versus ApoE-/-;Nf1+/-: 164.9 ± 16.8, n=7; P<.001), 
and these cells accounted for the majority of infiltrating cells in ApoE-/-;Nf1+/-  
aneurysms (Figure 2D). ApoE-/-;Nf1+/- mice also had a 2-fold increase in the 
accumulation of T cells and mast cells compared to ApoE-/- mice; however, these 
cells accounted for less than 5% of immune cells in aneurysms of ApoE-/-;Nf1+/- 
mice. Collectively, these data demonstrate that heterozygous inactivation of Nf1 
increases the frequency and severity of aneurysms with a corresponding 
increase in macrophage population. 
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Table 1 
Blood serum chemistry and atherosclerotic lesion assessment 
 Normal Chow Diet Atherogenic Diet 
 
      ApoE-/- ApoE
-/-
;Nf1+/- 
 
ApoE-/- ApoE
-/-
;Nf1+/- 
 
Body 
Mass (g) ND ND 
26.2 ± 1.3   
(n=9) 
 
25.54 ± 0.6 
(n=10) 
 
Total 
CholA 
462.6 ± 
11.2 (n=7) 
 
438.8 ± 
28.4 
(n=8) 
 
1576* ± 110.9 
(n=9) 
 
1458† ± 
81.2 
(n=10) 
 
LDL 
CholA 
345.4 ± 
24.8 (n=7) 
 
356.6 ± 8.1 
(n=8) 
 
1351* ± 92.2 
(n=9) 
 
1279† ± 
63.9 
(n=10) 
 
HDL 
CholA 
83.7 ± 4.2 
(n=7) 
 
75.8 ± 9.6       
(n=8) 
 
364.9* ± 174.4 
(n=9) 
 
167.8† ± 
34.6 
(n=10) 
 
TriglycerideA 
111.1 ± 6.1 
(n=7) 
 
88.0 ± 12.3     
(n=8) 
 
136.9 ± 12.3 
(n=9) 
 
150.7† ± 
10.4 (n=9) 
 
Fasting 
GlucoseA 
 
ND 
 
ND 
 
60.7 ± 4.2 (n=6) 
 
51.8 ± 3.0 
(n=6) 
 
Atherosclerotic 
Lesion Area   
(% of total 
aortic area) 
245.4 ± 
15.1 (n=7) 
223.8 ± 
22.8 (n=8) 
624.0* ± 118.6 
(n=9) 
523.8† ± 
33.3 
(n=10) 
 
*= P < 0.05 ApoE-/- NCD versus ApoE-/- Atherogenic Diet 
†= P < 0.05 ApoE-/-;Nf1+/- NCD versus ApoE-/-;Nf1+/- Atherogenic Diet 
A= Measured in mg/dL 
ND = Not Determined 
Chol = Cholesterol 
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Figure 1. ApoE-/-;Nf1+/- mice fed a high fat diet have augmented aneurysm 
formation. (A) Representative photographs of the aorta and its branches from 
ApoE-/- and ApoE-/-;Nf1+/- mice fed a normal chow diet (NCD) or a high fat diet 
(HFD). Red boxes identify areas of aneurysm formation magnified in the panels 
on right. Scale bars: 1mm. (B) Quantification of aneurysm incidence, *P<0.0001 
for NCD ApoE-/-;Nf1+/- (n= 10) versus HFD ApoE-/-;Nf1+/- (n=11). **P<0.01 for 
HFD ApoE-/- (n=10) versus HFD ApoE-/-;Nf1+/- (n=11). No statistical significance 
was observed (P=.08) for NCD ApoE-/- (n=10) versus HFD ApoE-/- (n=10). 
Analysis by Fisher’s exact test with Bonferroni correction. (C) Average number of 
aneurysms per HFD mouse, *P<0.001 for ApoE-/- (n=10) versus ApoE-/-;Nf1+/- 
(n=11) by Student’s t-test. (D) Severity index of aneurysms of HFD ApoE-/- (n=10) 
and HFD ApoE-/-;Nf1+/- (n=11). There was no aneurysm formation in NCD mice of 
either genotype. 
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Figure 2. ApoE-/-;Nf1+/- mice fed a high fat diet have augmented histological 
aneurysm formation. Representative photomicrographs of abdominal aortic 
cross-sections from ApoE-/- and ApoE-/-;Nf1+/- mice on NCD or HFD stained with 
(A) H&E, (B) van Gieson for elastin, (C) Masson’s trichrome for collagen or (D) 
anti-F4/80 for macrophages (brown cells, arrowheads). Arrowheads in B indicate 
degradation of the elastic lamina. Black boxes in B and D identify area that is 
magnified in lower panel. Scale bars: 50 µm. 
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Heterozygous inactivation of Nf1 amplifies the incidence and severity of 
aneurysm formation in angiotensin II-infused mice. 
 To dissect the cellular mechanism of aneurysm formation and to confirm 
the effect of Nf1 heterozygosity on aneurysm development in a more tractable 
system, we performed a second line of experiments in WT and Nf1+/- mice 
utilizing a different experimental model to interrogate disease pathogenesis. 
Angiotensin II (Ang II) infusion is another commonly used method of aneurysm 
induction and was adapted for use with modification (63, 98, 99). Infusion of Ang 
II induces inflammatory mediators and reactive oxygen species (ROS) within the 
arterial wall, producing abdominal aortic aneurysms that recapitulate human 
lesions (61, 95). 
 Infusion of Ang II increased aneurysm formation 3-fold in Nf1+/- mice 
compared to wild type mice (WT) (Figure 3A and 3B). Morphometric analysis of 
abdominal aortas from both genotypes revealed that Ang II-infused Nf1+/- mice 
had significantly larger aneurysms (Figure 4A and 4B). Further, Nf1+/- aneurysms 
display increased degradation of the elastic lamina and disorganized architecture 
which translated to a higher degree of aneurysm severity than WT aneurysms, 
which is reminiscent of lesions from NF1 patients (Figure 5A through 5C) (100). 
Importantly, Ang II infusion did not alter body weight or intra-arterial blood 
pressure in either genotype. Saline-infused Nf1+/- and WT mice did not form 
aneurysms (Figure 3A, 3B and 4A). These data indicate Nf1 heterozygosity 
augments Ang II-induced aneurysm formation. 
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Figure 3 
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Figure 3. Nf1+/- mice have increased Ang II-induced abdominal aortic aneurysm 
formation. (A) Representative photographs of the aorta and branches from saline 
or Ang II-infused WT and Nf1+/- mice. Boxes identify area magnified in lower 
panel. Scale bars: 1mm. (B) Quantification of aneurysm incidence. *P<0.0083 for 
saline-infused WT (n=24) versus Ang II-infused WT (n=29) and Ang II-infused 
Nf1+/- (n=31). **P<0.0083 for saline-infused Nf1+/- (n=16) versus Ang II-infused 
Nf1+/-. Analysis by Fisher’s exact test with Bonferonni correction. 
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Figure 4. Nf1+/- mice have larger Ang II-induced abdominal aortic aneurysms. 
(A) Maximum abdominal aortic diameter of saline or Ang II-infused WT and Nf1+/- 
mice. Clustering around 1mm represents animals without aneurysm formation. 
*P<0.05 for saline-infused Nf1+/- (n=16) versus Ang II-infused Nf1+/- (n=31). 
**P<0.05 for Ang II-infused WT (n=29) versus Ang II-infused Nf1+/- (n=31). No 
statistical significance was observed for saline-infused WT (n=24) versus Ang II-
infused WT (n=29). Analysis by one-way analysis of variance (ANOVA) with 
Tukey’s test. Error bars denote the mean ± SEM. (B) Representative 
photomicrographs of abdominal aortic cross-sections from saline and Ang II-
infused WT and Nf1+/- mice stained with H&E. 
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Figure 5. Nf1+/- mice display increased severity of Ang II-induced abdominal 
aortic aneurysms. (A) Representative photomicrographs of abdominal aortic 
cross-sections from saline and Ang II-infused WT and Nf1+/- mice stained with 
van Gieson. Boxed areas magnified in lower panel. Arrowheads indicate elastic 
lamina fragmentation. Scale bars: 50µm. (B) Grading of elastic lamina 
degradation in saline or Ang II-infused WT and Nf1+/- mice. *P<0.05 for saline-
infused Nf1+/- (n=5) or WT (n=5) versus Ang II-infused Nf1+/- mice (n=13). 
**P<0.05 for Ang II-infused WT (n=15) versus Ang II-infused Nf1+/- mice. No 
statistical significance was observed for saline-infused WT or Nf1+/- versus Ang 
II-infused WT. (C) Aneurysm severity for Ang II-infused WT (n=29) or Ang II-
infused Nf1+/- (n=31) mice. No aneurysms formed in saline-infused mice of either 
genotype. 
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Nf1+/- aneurysms are characterized by inflammatory cell infiltration, 
vascular smooth muscle cell expansion, and reactive oxygen species 
production. 
 NF1 patients and Nf1+/- mice have increased populations of circulating 
inflammatory monocytes and pro-inflammatory cytokines linked to aneurysm 
formation (20, 22). Therefore, we sought to characterize the cellular and 
structural composition of WT and Nf1+/- aneurysms. Histologic examination of 
Nf1+/- aneurysms demonstrated significant dilation and degradation of the aortic 
wall, including increased disruption of the elastic lamina and advential expansion 
when compared to WT aneurysms (Figure 5A through 5C). Importantly, Nf1+/- 
aneurysms contained 4-times the number of macrophages compared to WT 
(Figure 6A and 6B). Nf1+/- macrophages co-localized to sites of elastic lamina 
degradation, medial rupture and adventitial expansion, indicating their potential 
role in aneurysm formation (Figure 5A and 6A). Ang II infusion also induced a 
significant expansion of vascular smooth muscle cells (VSMCs) in the media of 
Nf1+/- aortas compared to WT (Figure 7A and 7B). Nf1+/- VMSC expansion is 
consistent with previous findings that Nf1+/- VSMCs exhibit increased proliferation 
and migration in response to cytokines secreted by macrophages and vascular 
wall cells implicated in CVD (20, 101). Finally, co-staining with α-smooth muscle 
actin (α-SMA) and anti-Mac-3 illustrated VSMC expansion was within and near 
the vessel media while macrophage infiltration was primarily in the adventia as 
expected (Figure 8) (102, 103). 
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Genetic studies demonstrate that VSMC and macrophage secretion of 
MMPs (50, 52, 53) and ROS (61, 94, 104) are important molecular triggers for 
extracellular matrix (ECM) remodeling and aneurysm induction. Given the 
increased density of VSMCs and macrophages in Nf1+/- aneurysms, we 
measured expression and activation of matrix metalloproteinase-2 (MMP-2) and 
matrix metalloproteinase-9 (MMP-9) in aortas harvested from Nf1+/- and WT mice 
infused with Ang II or saline. Ang II infusion increased MMP activity and 
preferentially amplified MMP-9 expression in Nf1+/- aneurysms when compared 
with Ang II-infused WT aneurysms as determined by in situ zymography and 
immunohistochemistry (IHC) (Figure 9A and 9B). In addition, gelatin zymography 
of abdominal aortic explants from Ang II-infused WT and Nf1+/- mice corroborated 
increases of MMP activity in both genotypes with significantly enhanced 
activation of MMP-9 in Nf1+/- aortas alone (Figure 9C). Amplified MMP-9 
expression in Nf1+/- aortas is an important observation since MMP-9 is largely 
derived from vessel wall macrophages (57, 105), which is consistent with the 
increased macrophage infiltration observed in Nf1+/- aneurysms.  
We next assessed ROS production in abdominal aortic cross-sections 
from Ang II and saline-infused Nf1+/- and WT mice with dihydroethidium (DHE), a 
superoxide probe. Ang II infusion significantly increased superoxide production in 
Nf1+/- aortas when compared with WT aortas, while superoxide production was 
nearly undetectable in the aortas from saline-infused Nf1+/- and WT aortas 
(Figure 10A and 10B). Collectively, these data demonstrate that Nf1 
heterozygous aneurysms have evidence of increased inflammatory cell infiltration, 
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MMP activation, and ROS production, which are linked to abnormal arterial 
remodeling and disease progression.  
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Figure 6 
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Figure 6. Nf1+/- mice have increased Mac3+ macrophage infiltration in abdominal 
aortic aneurysms. (A) Representative photomicrographs of abdominal aortic 
cross-sections from saline and Ang II-infused WT and Nf1+/- mice stained anti-
Mac-3 antibody (arrowheads). Boxed areas magnified in lower panel. Scale bars: 
50µm. (B) Quantification of Mac3-positive macrophages per high-power field 
(HPF) in saline or Ang II-infused WT and Nf1+/- mice. *P<0.05 for saline-infused 
Nf1+/- (n=5) versus Ang II-infused Nf1+/- mice (n=5). **P<0.05 for Ang II-infused 
WT (n=5) versus Ang II-infused Nf1+/- mice. No statistical significance was 
observed for saline-infused WT (n=5) versus Ang II-infused WT. Analysis by one-
way ANOVA with Tukey’s test. 
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Figure 7. Nf1+/- mice have increased vascular smooth muscle cells in abdominal 
aortic aneurysms. (A) Representative photomicrographs of abdominal aortic 
cross-sections from Ang II-infused WT and Nf1+/- mice, stained with anti-α 
smooth muscle actin (red) to identify VSMCs. Cell nuclei are counterstained with 
DAPI (blue) and auto-fluorescence of murine tissue is visible (green). Saline-
infused WT mice shown as control. Appearance of saline-infused Nf1+/- was 
similar to saline-infused WT staining. Scale bars: 50µm.  (B) Quantification of 
VSMCs from Ang II-infused WT (n=5) and Nf1+/- (n=5) mice; *P<0.05 for Ang II-
infused WT versus Ang II-infused Nf1+/-, by Student’s t-test.  
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Figure 8 
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Figure 8. Relative location of macrophages and vascular smooth muscle cells in 
abdominal aortic aneurysms. Representative photomicrographs showing co-
staining of Ang II-infused WT and Nf1+/- aortas with anti-α-SMA (red) and anti-
Mac-3 (green). Scale bars: 50µm. 
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Figure 9. Nf1+/- mice have increased MMP activity and increased MMP-2 and 
MMP-9 expression in abdominal aortic aneurysms. (A) Representative 
photomicrographs of abdominal aortic cross-sections from saline and Ang II-
infused WT and Nf1+/- mice. MMP activity (green) was visualized by in situ 
zymography (B) expression of MMP-2 and MMP-9 was detected by IHC staining 
with anti-MMP-2 (brown) and anti-MMP-9 (brown) antibodies. Scale bars: 50µm. 
(C) Representative zymogram showing abdominal aortic MMP-2 and MMP-9 
levels for saline and Ang II-infused WT and Nf1+/- mice. 
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Figure 10 
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Figure 10. Nf1+/- mice have increased superoxide formation in abdominal aortic 
aneurysms. (A) Representative photomicrographs of abdominal aortic cross-
sections from saline or Ang II-infused WT and Nf1+/- mice, showing superoxide 
production identified by in situ DHE staining (red). Auto-fluorescence of murine 
tissue is visible (green). (B) Quantification of ethidium fluorescence. *P<0.05 for 
Ang II-infused Nf1+/- (n=9) versus saline-infused WT (n=5) and Nf1+/- (n=3). 
**P<0.05 for Ang II-infused Nf1+/- versus Ang II-infused WT (n=8). Analysis by 
one-way ANOVA with Tukey’s test. 
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Heterozygous inactivation of Nf1 in myeloid cells alone is sufficient to 
recapitulate Nf1+/- aneurysm formation. 
Nf1+/- mice have increased aneurysm formation characterized by 
increased macrophages and VSMCs and their secretory products, which are 
known to promote disease progression. Based on these observations, we 
generated transgenic mice with a single copy of the Nf1 gene ablated in VMSCs 
or myeloid cells alone to determine the role of Nf1 heterozygosity in VSMCs and 
myeloid cells on aneurysm formation. Briefly, Nf1fl/fl mice containing conditional 
Nf1 alleles susceptible to Cre-mediated recombination (89) were inter-crossed 
with SM22cre or LysMcre transgenic mice, generating Nf1fl/+;SM22cre and 
Nf1fl/+;LysMcre progeny with Nf1 heterozygous VSMCs (106) and myeloid cells 
(107), respectively.  Nf1fl/fl mice underwent efficient Cre-mediated recombination 
when crossed with LysMcre (Figure 11) or SM22cre mice (35). Importantly, 
LysMcre-mediated recombination was seen in the aortic adventia, a known 
location for macrophages, while the aortic media showed minimal LysMcre-
mediated recombination. 
Nf1fl/+;SM22cre and Nf1fl/+;LysMcre mice were infused with Ang II or saline 
and evaluated for aneurysm formation with controls (WT and Nf1+/- mice). 
Nf1fl/+;LysMcre mice infused with Ang II developed large aneurysms recapitulating 
the phenotype of Nf1+/- mice, while Nf1fl/+;SM22cre mice produced less severe 
aneurysms similar to WT mice (Figure 12A through 12D). Specifically, a 2.5-fold 
increase in AAA incidence was observed in Nf1fl/+;LysMcre mice compared with 
Nf1fl/+;SM22cre and WT mice (Figure 12B). Saline infusion failed to produce aortic 
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aneurysms in all genotypes. Additionally, Ang II-infused Nf1fl/+;LysMcre 
aneurysms displayed similar maximal dilation and aneurysm severity when 
compared to Nf1+/- mice (Figure 12C and 12D). 
Histologic examination of H&E and van Gieson stained arterial cross-
sections of Nf1fl/+;LysMcre aneurysms revealed increased elastic lamina 
degradation and adventitial expansion, similar to aneurysms harvested from Ang 
II-infused Nf1+/- mice (Figure 13A through 13C). Cross-sections from 
Nf1fl/+;LysMcre aortas demonstrated increased macrophage density similar to 
Nf1+/- aneurysms, while Nf1fl/+;SM22cre and WT mice contained significantly 
reduced macrophage numbers (Figure 14A). Similar to Nf1+/- mice, macrophages 
in Nf1fl/+;LysMcre mice were in close proximity to areas of advential expansion and 
elastic lamina degradation (Figure 13B and 14A). Additionally, Nf1fl/+;LysMcre and 
Nf1fl/+;SM22cre displayed similar MMP activity and DHE staining as Nf1+/- and WT 
mice, respectively (Figure 14B through 14D). Collectively, these data provide 
genetic evidence that heterozygous inactivation of Nf1 in myeloid cells alone is 
sufficient to recapitulate Nf1+/- aneurysm formation in vivo, thereby implicating 
Nf1+/- monocytes and macrophages as the cellular trigger for aneurysm 
formation.  
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Figure 11 
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Figure 11. Nf1fl/+;LysMcre mice display efficient recombination. 
PCR analysis of abdominal aorta shows the specific location of the cre-mediated 
recombination of floxed Nf1 gene in the vascular adventitia of 3 month old, non-
infused Nf1flox/+;LysMcre mice. Arrowhead indicates cre-mediated recombination 
(280bp band). Nf1flox/+;SM22cre VSMCs were used as positive control.  
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Figure 12. Heterozygous inactivation of Nf1 in myeloid cells alone is sufficient to 
recapitulate Nf1 abdominal aortic aneurysm formation. (A) Representative 
photographs of abdominal aortas from Ang II-infused WT, Nf1+/-, Nf1fl/+;LysMcre 
and Nf1fl/+;SM22cre mice. Scale bars: 1mm. Saline-infused WT, Nf1+/-, 
Nf1fl/+;LysMcre and Nf1fl/+;SM22cre mice did not form AAAs. (B) Quantification of 
AAA incidence. (C) Maximum abdominal aortic diameter of Ang II-infused WT, 
Nf1+/-, Nf1fl/+;LysMcre and Nf1fl/+;SM22cre mice. Clustering around 1mm represents 
animals without AAA formation.  *P<0.05 for Ang II-infused WT (n=10) versus 
Ang II-infused Nf1+/- (n=9), and Ang II-infused WT versus Nf1fl/+;LysMcre (n=15). 
**P<0.05 for Ang II-infused Nf1fl/+;SM22cre (n=10) versus Ang II-infused Nf1+/-, 
and Ang II-infused Nf1fl/+;SM22cre versus Ang II-infused Nf1fl/+;LysMcre. Analysis 
by one-way ANOVA with Tukey’s test. Error bars denote mean ± SEM. For B and 
C, no statistical significance was observed for Ang II-infused WT versus Ang II-
infused Nf1fl/+;SM22cre, or Ang II-infused Nf1+/- versus Ang II-infused 
Nf1fl/+;LysMcre. (D) Severity index of AAAs for Ang II-infused WT (n=10), Nf1+/- 
(n=9), Nf1fl/+;LysMcre (n=15) and Nf1fl/+;SM22cre mice (n=10). 
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Figure 13. Nf1fl/+;LysMcre mice have enlarged and more severe abdominal aortic 
aneurysms similar to Nf1+/- mice. (A) Representative photomicrographs of 
abdominal aortic cross-sections from Ang II-infused WT, Nf1+/-, Nf1fl/+;LysMcre 
and Nf1fl/+;SM22cre, stained with H&E or (B) van Gieson for elastin. Boxes identify 
area that is magnified in lower panel. Arrowheads identify fragmentation of elastic 
lamina in van Gieson photomicrographs and yellow staining identifies ECM. 
Saline infusion did not produce AAAs in any genotype. Scale bars: 50µm. (C) 
Grading of elastic lamina degradation in Ang II-infused Nf1fl/+;LysMcre and 
Nf1flox/+;SM22cre mice. *P<0.05 for Nf1fl/+;LysMcre (n=12) versus Nf1fl/+;SM22cre 
(n=9). No statistical significance in elastic lamina degradation grade was 
observed between Nf1fl/+;LysMcre and Nf1+/- mice or Nf1fl/+;SM22cre and WT mice. 
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Figure 14. Nf1fl/+;LysMcre aneurysms contain increased macrophage infiltration, 
MMP activity and superoxide levels similar to Nf1+/- mice. (A) Representative 
photomicrographs of abdominal aortic cross-sections from Ang II infused WT, 
Nf1+/-, Nf1fl/+;LysMcre, and Nf1fl/+;SM22cre mice stained with anti-Mac-3 antibody 
for macrophages (brown cells, arrowheads). Black boxes specify area that is 
magnified in lower panel. Scale bars: 50 µm. (B) Representative 
photomicrographs showing MMP activity in Nf1fl/+;LysMcre and Nf1fl/+;SM22cre 
mice. Scale bars: 50µm. (C) Representative photomicrographs of abdominal 
aortic cross-sections from Ang II-infused Nf1fl/+;LysMcre and Nf1fl/+;SM22cre mice, 
showing superoxide production identified by in situ DHE staining (red). Auto-
fluorescence of murine tissue is visible (green). Scale bars: 50µm. (D) Bar graph 
depicts quantification of ethidium fluorescence. 
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DISCUSSION 
 
Cardiovascular disease is an important under recognized non-neoplastic 
manifestation in NF1 patients, which contributes significantly to debilitating 
morbidities and early mortality and encompasses a variety of pathologies (23). 
Many of these vascular pathologies, including aneurysm formation and arterial 
stenosis, are often clinically silent, making an accurate measure of both disease 
frequency and burden difficult to determine (33). Thus, an understanding of the 
initiation and progression of these vascular pathologies is critical to facilitate 
cardiovascular disease risk screening, early recognition, and intervention in NF1 
patients. 
A major limitation in understanding NF1 aneurysm disease has been the 
lack of an animal model that closely recapitulates the human disease. In the 
current study, two common murine models of aneurysmal disease were adapted 
to Nf1 heterozygous mice, which provide novel approaches to examine the 
cellular and molecular mechanisms that regulate NF1 aneurysm formation. In 
both experimental models, histologic analysis of Nf1+/- aneurysms revealed 
increased macrophage infiltration, MMP-9 expression and activation, and ROS 
production, which are molecular and cellular signatures of aneurysm formation 
observed in other experimental animals independent of neurofibromin deficiency 
(56, 57, 108, 109). These observations suggest that vascular inflammation and 
macrophage secretory products are critical factors in NF1 aneurysmal disease 
consistent with aneurysm formation in other diseases with chronic inflammation 
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(56, 64, 109). This is an important observation since it has been previously 
demonstrated that NF1 patients without known cardiovascular disease have 
increased numbers of CD14dimCD16hi circulating pro-inflammatory monocytes 
and elevated levels of inflammatory cytokines including IL1β and IL-6 (22), which 
have been previously linked to vascular disease in non-NF1 subjects in large 
population studies (37).   
To directly determine the contribution of neurofibromin-deficient myeloid 
cells to Nf1+/- aneurysm formation, lineage-restricted transgenic mice were 
utilized to specifically ablate a single Nf1 allele in myeloid cells alone. 
Heterozygous inactivation of the Nf1 gene in myeloid cells alone was sufficient to 
reproduce the aneurysm phenotype observed in Nf1+/- mice. Importantly, despite 
significant expansion of Nf1+/- VSMCs in arterial walls, aneurysm frequency and 
severity in transgenic mice harboring a single Nf1 allele in VSMCs were similar to 
WT controls. Collectively, this genetic study directly implicates neurofibromin-
deficient myeloid cells as the critical cellular effectors of aneurysm formation in 
Nf1+/- mice. 
Neurofibromin negatively regulates the Ras signaling cascade in multiple 
mammalian cell types by accelerating the conversion of active Ras-GTP to its 
inactive GDP confirmation (5). Loss of this function in Nf1 heterozygous cells and 
subsequent augmentation of Ras signaling and activation of its downstream 
effectors including the Ras-Mek-Erk and Ras-PI-3K pathways, render cells 
hypersensitive to a number of growth factors contributing to the variety and the 
complexity of disease manifestations observed in NF1 patients (12, 22, 34, 101, 
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110-112). Interestingly, myeloid cells and their progenitor cells are particularly 
sensitive to Ras activation and demonstrate multiple gain-of-function phenotypes 
contributing to myelo-proliferative disease, plexiform neurofibroma formation, 
bone disease, and vasocclusive disease in various animal models of NF1 
disease (22, 34, 111-114). Relevant to the current study, myeloid cells secrete 
growth factors and cytokines that are well established mediators of 
cardiovascular disease including atherosclerosis (115), vessel occlusion (34), 
and aneurysm formation (116). In view of our recent report that neurofibromin-
deficient myeloid cells are the primary mediators of Nf1+/- arterial stenosis (34), 
the observation that Nf1+/- mice develop more frequent and severe aneurysms 
mediated via heterozygous inactivation of Nf1 in myeloid cells alone highlights 
the global pathogenic consequences of neurofibromin-deficient myeloid cells to 
diverse NF1 clinical manifestations, including cardiovascular disease.  
Myeloid cell recruitment and infiltration of the vessel wall to initiate elastic 
lamina degradation are essential steps in the pathogenesis of aneurysm 
formation (56). Ang II facilitates aneurysm formation via activation of VSCMs and 
monocytes, which secrete cytokines and chemotactic factors leading to 
enhanced production of MMPs, resulting in vascular inflammation and vessel wall 
remodeling (63, 117). Though several molecular ligand-receptor signaling 
cascades contribute to the progression of aneurysmal disease, pharmacologic 
inhibition or genetic disruption of monocyte chemotactic protein-1 (MCP-1) 
binding to its primary receptor, CCR2, significantly reduces aneurysm formation 
(117-119). This signaling axis is particularly interesting since pro-inflammatory 
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monocytes co-express high cell surface levels of the CCR2 receptor (120, 121). 
Therefore, increased CD14dimCD16hi pro-inflammatory monocytes found within 
NF1 patients may be an important factor leading to the increased incidence of 
CVD and aneurysm formation. Whether Nf1+/- macrophages are mobilized from 
the bone marrow, to the blood and into the vascular wall or proliferate locally 
within the wall of the aorta from the recently described common myeloid 
progenitor remains to be elucidated (117, 122). 
Another striking observation in this study is the increased production of 
ROS and MMPs in Nf1+/- vessel walls and developing aneurysms. Production of 
ROS and MMPs by various cell types is known to be critical for aneurysm 
formation in several model systems. Genetic or pharmacologic disruption of 
MMP-2 and MMP-9 in mice decreases aneurysm formation (58, 123). These 
findings suggest that MMPs, released by resident and infiltrating vascular wall 
cells, are key molecular events in aneurysm formation. Given these observations, 
our current study suggests that increased levels of MMP-9 observed in Nf1 
heterozygous aneurysms may play a significant role in NF1 aneurysm 
progression, warranting further investigation to examine whether genetic 
modification and pharmacologic inhibition of MMP-9 activity alone can inhibit 
aneurysm initiation and progression in our Nf1 experimental system.  
Increased ROS levels are also detected in various human and murine 
cardiovascular lesions including aneurysms (61, 94). Moreover, evidence 
suggests that ROS overproduction facilitates MMP activation and contributes to 
vascular inflammation and vessel wall remodeling (124). Loss of neurofibromin 
	  	   60 
has been shown to directly stimulate the adenylyl cyclase/cyclic AMP pathway 
amplifying mitochondrial ROS production in Drosophila melanogaster, 
independent of the Ras/Raf pathway (125). Conversely, constitutively active Ras 
mutations dramatically increase ROS production in mammalian hematopoietic 
progenitor cells via NADPH oxidase (NOX2) activation without increasing 
mitochondrial ROS (126). Although these studies differ in regards to the source 
of ROS production due to neurofibromin deficiency, increased ROS from either 
source has the ability to activity MMPs in the vascular wall potentially leading to 
aneurysm formation. These prior experimental observations highlight the need to 
unravel the potentially complicated redox state within neurofibromin-deficient 
cells, which could trigger oxidant stress in various tissues including the vessel 
wall.  
Previous studies have also identified increased expression of ROS 
producing-NOX subunits p22phox and p47phox within aortic aneurysms of non-NF1 
patients and mice (61, 127). Genetic disruption of p47phox significantly diminishes 
oxidative stress and subsequent aneurysm formation in mice infused with Ang II 
(64). These data suggest a role of NOX proteins as producers of ROS in 
aneurysm pathogenesis, indicating potential sources for the observed Nf1+/- 
production of ROS. Further, these studies also provide rationale for transgenic 
murine studies using cell specific deletion of p47phox and gp91phox within 
endothelial cells, VSMCs and/or monocytes/macrophages in Nf1+/- mice to test 
whether specific NOX isoform(s) contribute to ROS overproduction and 
subsequent aneurysm development.  
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Together, the current study establishes the first animal models of NF1 
aneurysm disease and identifies myeloid cells as the critical cellular effectors. 
Given the utility of these Nf1 aneurysm models, additional studies will refine the 
biochemical triggers for NF1 vascular disease using genetic and pharmacologic 
approaches. These insights could provide the pre-clinical data for future human 
studies in NF1 patients to identify early cardiovascular disease and potential 
therapeutic strategies for prevention and treatment of vascular disease. 
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CHAPTER TWO 
IDENTIFICATION OF EXCESSIVE INFLAMMATION AND OXIDATIVE STRESS 
AS CRITICAL BIOCHEMICAL PROCESSES LEADING TO NF1+/- ANEURYSM 
FORMATION 
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INTRODUCTION 
 
Cardiovascular Disease and Oxidative Stress. 
 Reactive oxygen species (ROS), including superoxide, hydrogen peroxide, 
peroxide, hydroxyl radical and hydroxyl ion, play an important role as signaling 
molecules intracellularly and intercellularly in response to growth factors and 
chemical stimulation (128-130). ROS can rapidly react and oxidize lipids and 
proteins resulting in chemical and structural modification which under appropriate 
redox regulation can lead to proper signal transduction (131). However, when the 
redox state is not properly regulated oxidation of lipids, proteins and DNA can 
occur in a detrimental manner and has been implicated in many diseases 
processes including cardiovascular disease (132), neurodegeneration (133), 
diabetes (134) and aging (135). The production of ROS results primarily from 
professional oxidases, such as those in the NADPH oxidase (NOX) family, and 
as a byproduct of inefficient aerobic metabolism by mitochondria (136). 
 The NOX family of professional oxidases includes NOX1, NOX2, NOX3, 
NOX4, NOX5, dual oxidase-1 (DUOX1) and DUOX2. While the NOX proteins 
produce superoxide, the DUOX proteins may use superoxide generated by NOX 
proteins to produce hydrogen peroxide (137, 138). NOX2 is the most thoroughly 
studied enzyme of the NOX family and is found in phagocytic cells producing 
superoxide, which is expelled during the oxidative burst as part of innate 
immunity (139). The superoxide-producing active complex of NOX2 is made up 
of 6 subunits including gp91phox and p22phox (flavocytochome b558) which are 
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located in the plasma membrane, as well as 4 regulatory subunits that reside in 
the cytoplasm while inactive including p40phox, p47phox, p67phox, and Rac 
(140). Of note, chronic granulomatous disease (CGD) patients are characterized 
by the absence of the ph91phox component of NOX2, resulting in the inability to 
clear bacteria and debris. Additionally, CGD patients develop granulomas due to 
a defect in the potent oxidative burst resulting in granuloma formation, indicating 
the physiological importance of this complex (141).  
 Regulation of NOX2 is multidimensional in both cellular location and signal 
transduction. Inactive flavocytochome b558 is stored within intracellular granules 
while p40phox, p47phox and p67phox make up an inactive dephosphorylated 
complex within the cytoplasm (142, 143). Inactive Rac is GDP-bound and 
complexed with Rho-GDI (144). Upon stimulation, granules containing 
flavocytochome b558 fuse to phagosomes and interact with the phosphorylated 
p47phox, p40phox, p67phox complex and active GTP-bound Rac forming the 
active oxidase (145). Phosphorylation has been shown to be dependent on Ras-
Mek-Erk signaling pathway indicating a potential role in NF1 for inappropriate 
activation of NOX2 (146). Phosphatidylinositol-3,4,5-triphosphate which is 
generated by PI-3K, also under control of neurofibromin, is required to bind with 
p40phox to allow for association of the phosphorylated p40phox, p47phox and 
p67phox complex with the plasma membrane and flavocytochome b558 (147). 
Finally, Rac activation has also been shown to be important in cross-talk 
between the Ras-Mek-ERK pathway and the PI-3K pathway further linking 
neurofibromin regulated pathways and NOX2 activation (148). 
	  	   65 
 Although many members of the NOX family are currently being 
investigated for their role in CVD, the main focus has been on the role of NOX2 
due to its ability to produce the largest amount of superoxide in a short time, as 
well as its expression in phagocytes, which are commonly found associated with 
and implicated in cardiovascular lesion formation. Immunohistochemical studies 
have identified increased expression of p22phox and p47phox within aortic 
aneurysms of non-NF1 patients and mice (61, 127). Additionally, in vivo studies 
of p47phox-deficient mice implicate p47phox as a critical mediator of aneurysm 
formation (64). These findings underscore the importance of the NOX2 subunits, 
in the development of aneurysmal tissue and also show that inhibition may be a 
viable therapeutic target. 
 Mitochondrial superoxide formation via aerobic respiration may also be an 
important contributor to CVD (149). Mitochondria produce ATP via a proton 
gradient established through oxidative phosphorylation by transferring electrons 
from NADH or FADH2 to oxygen, producing water (150). In normal conditions 1 to 
2% of electrons form superoxide rather than water and are quickly dismutated to 
hydrogen peroxide by superoxide dismutase. If the electron transport chain 
becomes uncoupled, a large amount of superoxide can be released into the 
cytoplasm, leading to intracellular, intercellular and extracellular damage of lipids, 
protein, and DNA. Regulation of mitochondrial respiration, and therefore ROS 
release, has been shown to be mediated via the adenylyl cyclase/cyclic 
AMP/protein kinase A pathway. Decreases in neurofibromin lead to a reduction in 
protein kinase A and decreased mitochondrial respiration and greater ROS 
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production. The converse was also true when Nf1 was overexpressed in 
Drosophilia or cyclic AMP was supplemented; efficient mitochondrial respiration 
was increased and ROS was decreased leading to a protective oxidative state 
and increased lifespan (125).  
 Overall, oxidative stress displays a causal relationship in cardiovascular 
disease and in affected individuals in the general population. Studies presented 
above indicate that NF1 patients may have increased oxidative burden compared 
to the general population, resulting in the earlier onset and increased severity of 
CVD. Mechanisms leading to the oxidative burden may be complexed and from 
multiple cellular sources warranting further investigation to identify therapeutic 
targets. 
 
HMG-CoA Reductase inhibitors and Cardiovascular Disease. 
 HMG-CoA Reductase inhibitors, or statins, were originally developed as a 
potential cancer treatment to attenuate oncogenic Ras activity by reducing 
isoprenoid synthesis, an intermediate in cholesterol synthesis, that is necessary 
for proteins to interact with the plasma membrane (151). Statins have a long 
history of being used to reduce cholesterol levels and therefore reduce the risk of 
coronary artery disease (CAD) in patients (152). It was believed that the 
cholesterol lowering affect of statins was the mechanism of reduced CAD in 
patients on statins. More recently, large clinical studies have noted that subjects 
receiving statins have a greater protection from CAD than placebo subjects with 
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similar cholesterol levels, indicating a mechanism independent of cholesterol 
reduction (153).  
Several hypotheses exist explaining the mechanisms of the observed 
pleotropic effects of statins, which seem to work in concert to provide 
cardiovascular protection. It is hypothesized that of HMG-CoA reductase 
inhibition reduces the amount of lipid intermediates in the cholesterol synthesis 
pathway, including geranyl pyrophosphate, farnesyl pyrophosphate and 
isopentenyl pyrophosphate(151). Many proteins rely on post-translational 
modification and attachment of these lipids to enable trafficking and membrane 
binding within the cell. Importantly, Ras and Ras-like proteins, including Rho and 
Rac, are heavily dependent on post-translational prenylation for proper 
functioning (151, 154). Reduction in Ras and Rac activity could lead to reduced 
NOX2 activation and explain the antioxidant affects of statins (155). In addition to 
cholesterol and possible ROS reductions, statins have multiple potential effects 
on vascular endothelium. Hypercholesterolemia impairs nitric oxide synthesis 
and release, both critical functions to multiple components of athrogenesis (156-
158). Importantly, decreased nitric oxide synthesis allows for vasoconstriction, 
clot formation, VSMC proliferation and leukocyte recruitment, all hallmarks of 
both atherosclerosis and aneurysm formation (159). Statins have been shown to 
directly upregulate endothelial nitric oxide synthase leading to proper functioning 
of the endothelium, even before cholesterol levels have been reduced (160, 161). 
Overall, HMG-CoA reductase inhibition has beneficial effects in maintaining 
vessel wall homeostasis and reducing CVD. 
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Apocynin and Cardiovascular Disease. 
 Oxidative stress is a known component of many forms of cardiovascular 
disease. Antioxidant therapy has shown encouraging potential in various murine 
models of cardiovascular disease but has translated poorly to the clinic (155). 
Apocynin (4-hydroxy-3methoxy-acetophenone), a plant extract, has been shown 
to function as a potent antioxidant (162). Apocynin is a monomer that is thought 
to be a general antioxidant in this natural form; however, in cells which express 
myeloperoxidase apocynin can be dimerized or trimerized, both of which display 
the specific ability to block the association of p47phox with gp91phox thereby 
inhibiting superoxide formation by NOX2 (163). Myeloperoxidase is expressed in 
many hematopoietic cell types including macrophages, monocytes and 
neutrophils (164, 165). Importantly, myeloperoxidase is not expressed in VSMCs 
or endothelial cells indicating the majority of benefit seen in studies utilizing 
apocynin were largely from NOX2 inhibition in myeloid cells (166).  
 Apocynin has shown efficacy in the treatment of CVD in multiple animal 
models. In a rat model of hypertension, apocynin attenuated vascular wall 
superoxide formation, eliminating hypertension by allowing nitric oxide to diffuse 
freely, restoring normal VSMC relaxation (167, 168). Apocynin has also been 
found to reduce atherosclerotic progression in hypercholesterolemic mice, 
indicating the importance of ROS in those disease processes while highlighting 
the ability of apocynin to inhibit multiple types of CVD. Although apocynin has 
shown impressive efficacy in mouse models of CVD, no clinical trials have 
evaluated its use in human CVD. Currently, only one human clinical trial has 
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been completed, which investigated inhaled apocynin in mild asthmatics. The 
study observed no adverse effects of apocynin administration, as well as a 
reduction of hydrogen peroxide, nitrate and nitrite in exhaled breath condensate 
up to 2 hours after nebulization (169). By suggesting that apocynin is well 
tolerated in humans and can lead to a reduction in ROS, this trial provides a 
strong case for further investigation into potential uses for apocynin and future 
clinical trials. 
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MATERIALS AND METHODS 
 
Patient Recruitment. 
NF1 patients were recruited by the Indiana University NF1 Clinic at Riley 
Hospital for Children. All patients received a physical examination and a medical 
history was taken to confirm the diagnosis of NF1 according to the NIH clinical 
criteria (14, 15). Patients with a history of cancer, on anti-cancer drugs or 
pregnant were excluded from the study. All patients gave informed consent prior 
to participation in the study. 
 
Comet assay. 
Blood samples were collected from NF1 patients (37.6±9.7 years) and sex 
and age-matched controls (40.2±8.1 years) into EDTA vacutainer tubes (BD 
Biosciences). Mononuclear cells from approximately 16mLs of blood were 
isolated by centrifugation using Ficoll-Paque Plus (GE Healthcare) (170). 
Mononuclear cells were assayed for oxidative DNA damage as previously 
described, with modification (171). Following cellular lysis, slides were treated 
Formamidopyrimidine DNA glycosylase (FPG) which recognized and removed 
oxidized purines, causing a DNA break (172). 
 
Simvastatin administration. 
When indicated, simvastatin (Besse, OH) was administered as a 
suspension in water at 1 mg/kg/day via oral gavage beginning 7 days prior to 
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Ang II or saline infusion and continued throughout the course of experimentation. 
Water was administered via oral gavage to control mice in an equivalent volume 
as simvastatin.   
 
Apocynin administration. 
When indicated, Apocynin (also known as acetovanillone, 100mg/kg/day, 
Arcos Organics) was administered in drinking water beginning 7 days prior to 
Ang II or saline infusion and continued throughout the course of experimentation. 
Control mice received water at a similar volume. 
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RESULTS 
 
NF1 patients have evidence of oxidative stress in white blood cells. 
 NF1 patients without known cardiovascular disease have evidence of 
chronic vascular inflammation as evidenced by increased circulating pro-
inflammatory monocytes (22). Other disease processes characterized as having 
chronic vascular inflammation, such as diabetes, have been linked to increase 
oxidative stress (173). Therefore, we sought to investigate markers of oxidative 
stress in white blood cell samples from NF1 patients using the comet assay to 
analyze DNA damage. Briefly, cells are dispersed into individual cells and 
embedded in agarose on a microscope slide and lysed. Formamidopyrimidine 
DNA glycosylase (FPG) was added to cleave any oxidized DNA bases. Upon 
electrophoresis large DNA strands will not be able to move through the agar 
while smaller DNA pieces, caused by FPG cleavage, will migrate forming a 
comet tail-like appearance which can be quantified to asses oxidative DNA 
damage (172). NF1 patients displayed nearly a 2-fold increase in the amount of 
oxidative DNA damage as compared to control patients (Figure 15). This data 
indicates that circulating white blood cells are overproducing ROS even before 
differentiating to macrophages during extravasation into the vessel wall. 
Additionally, this data supports our previous hypothesis that myeloid cells are 
predominant producer of ROS in the vessel wall. 
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Figure 15 
 
 
 
	  	   74 
Figure 15. NF1 patients have increased DNA damage.  
Quantification of mean comet tail moment in white blood cells from NF1 and 
control patients. *P<0.05 for NF1 (n=10) versus control (n=28). 
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Simvastatin attenuates Ang II-induced AAA formation in Nf1+/- mice. 
HMG-CoA reductase inhibitors are clinically efficacious in the prevention 
of several manifestations of CVD, including aneurysm formation (174), which is in 
part attributable to their anti-inflammatory and antioxidant properties (175). 
Recent studies revealed that daily statin therapy significantly reduces arterial 
stenosis in Nf1+/- mice in part by inhibiting macrophage functions central to 
disease progression (34). Therefore, we tested whether simvastatin would 
reduce Nf1+/- aneurysm formation given our genetic data implicating the essential 
function of macrophages in both the initiation and progression of aneurysmal 
disease as well as previous findings of chronic inflammation and oxidative stress. 
WT and Nf1+/- mice were treated with daily low-dose simvastatin (1 mg/kg/day) or 
water for 7 days prior to initiation of Ang II infusion and continued for 35 days. 
Low-dose simvastatin reduced AAAs in Ang II-infused Nf1+/- mice by greater than 
2-fold compared to water-treated controls (Figure 16A, 16B and 17A) without 
affecting blood pressure or serum cholesterol levels. Corresponding decreases in 
aortic diameter and severity in Ang II-infused Nf1+/- mice were also observed 
(Figure 16C and 16D). There was no significant difference in AAA incidence, 
maximum aortic diameter, or severity in Ang II-infused WT mice in either 
treatment group (Figure 16A through 16D). However, simvastatin treatment 
reduced arterial remodeling, macrophage infiltration (Figure 17A through 17C) 
MMP-9 expression and activation, and ROS production (Figure 18A through 
18D) in arterial cross-sections from Nf1+/- mice when compared to water 
treatment. These results demonstrate that simvastatin prevents Ang II-induced 
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AAA formation in Nf1+/- mice, providing a potential therapeutic for NF1 
aneurysmal disease. 
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Figure 16. Simvastatin reduces Ang II-induced Nf1+/- abdominal aortic 
aneurysms. (A) Representative photographs of abdominal aortas from water or 
simvastatin-treated, Ang II-infused WT and Nf1+/- mice. Scale bars: 1mm. (B) 
Quantification of aneurysm incidence in water or simvastatin-treated, Ang II-
infused mice. (C) Maximum abdominal aortic diameter of water or simvastatin-
treated, Ang II-infused WT and Nf1+/- mice. Clustering around 1mm represents 
animals without aneurysm formation.  *P<0.05 for water-treated WT (n=17) 
versus water-treated Nf1+/- (n=22). **P<0.05 for water-treated Nf1+/- versus 
simvastatin-treated Nf1+/- (n=10). Analysis by one-way ANOVA with Tukey’s test. 
Error bars denote the mean ± S.E.M. For C, no statistical significance was 
observed for water-treated WT versus simvastatin-treated WT (n=13). (D) 
Severity index of AAAs of Ang II-infused WT and Nf1+/- mice treated with water 
(WT, n=17; Nf1+/-, n=22) or simvastatin (WT, n=9; Nf1+/–, n=10). For B-D, saline-
infused WT or Nf1+/- mice in either treatment group did not form aneurysms. 
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Figure 17 
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Figure 17. Simvastatin reduces Ang II-induced Nf1+/- abdominal aortic 
aneurysms and macrophage infiltration. Representative photomicrographs of 
abdominal aortic cross-sections from water or simvastatin-treated, Ang II-infused 
WT and Nf1+/- mice stained with (A) H&E, (B) van Gieson for elastin or (C) anti-
Mac-3 (arrowheads). Boxes specify area magnified in lower panel. Saline-infused 
WT and Nf1+/- mice treated with water or simvastatin did not produce aneurysms. 
In A, arrowheads identify fragmentation of elastic lamina and yellow staining 
identifies ECM. Scale bars: 50µm. 
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Figure 18 
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Figure 18. Simvastatin attenuates Ang II-induced Nf1+/- MMP expression and 
activation and superoxide production. (A) Representative photomicrographs of 
abdominal aortic cross-sections from water or simvastatin treated, Ang II-infused 
WT and Nf1+/- mice. MMP activity (green) was visualized by in situ zymography 
and expression of MMP-2 and MMP-9 was detected by IHC staining with anti-
MMP-2 (brown) and anti-MMP-9 antibodies (brown). Scale bars, 50µm. (B) 
Representative zymogram showing abdominal aortic MMP-2 and MMP-9 levels 
from water or simvastatin treated, Ang II-infused WT and Nf1+/- mice. (C) 
Representative photomicrographs of abdominal aortic cross-sections from water 
or simvastatin treated, Ang II-infused WT and Nf1+/- mice showing ROS identified 
by in situ DHE staining (red). Auto fluorescence of murine tissue is visible 
(green). (D) Quantification of ethidium fluorescence for simvastatin-treated, Ang 
II-infused WT and Nf1+/-. 
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Apocynin attenuates Ang II-induced AAA formation in Nf1+/- mice. 
Increased production of ROS has been demonstrated in several animal 
models of CVD and antioxidant therapy has shown some utility in reversing many 
of these processes (65). Based on our observation that NF1 patients have 
increased oxidative DNA damage and that Nf1+/- aortas have evidence of 
increased ROS in response to Ang II infusion, we sought to explore the ability of 
antioxidant therapy, using apocynin, in attenuating Nf1+/- aneurysm formation. 
Though generally recognized as a non-specific antioxidant, recent evidence 
suggests that apocynin may inhibit superoxide production in cells containing 
myeloperoxidase, including macrophages and monocytes (166, 176). 
 WT and Nf1+/- mice were treated with apocynin for 7 days prior to initiation 
of Ang II infusion and continued for 35 days thereafter. Apocynin reduced AAAs 
in Ang II-infused Nf1+/- mice by greater than 2-fold compared to water-treated 
controls, while apocynin did not have a significant effect on WT mice (Figure 19A 
and 19B). Additionally, decreases in both maximum abdominal aortic diameter 
and aneurysm severity were also noted in apocynin-treated Nf1+/- mice while 
apocynin-treated WT mice did not display a difference in either parameter (Figure 
19C and 19D). Remodeling of the arterial wall, macrophage infiltration and ROS 
production was significantly reduced in apocynin-treated Nf1+/- mice when 
compared to water-treated controls (Figure 20 and 21). These results identify 
overproduction of ROS as a significant contributor to Nf1+/- aneurysm formation 
and provide evidence that antioxidants may be a viable therapeutic option. 
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Figure 19. Apocynin reduces Ang II-induced Nf1+/- abdominal aortic aneurysms.  
(A) Representative photographs of abdominal aortas from water or apocynin-
treated, Ang II-infused WT and Nf1+/- mice. Scale bars: 1mm. (B) Quantification 
of aneurysm incidence in water or apocynin-treated, Ang II-infused mice. 
*P<0.0083 for water-treated Nf1+/- (n=23) versus apocynin-treated Nf1+/- (n=26). 
Analysis by Fisher’s exact test with Bonferroni Correction. (C) Maximum 
abdominal aortic diameter of water or apocynin-treated, Ang II-infused WT and 
Nf1+/- mice. Clustering around 1mm represents animals without aneurysm 
formation. *P<0.05 for water-treated WT (n=14) versus water-treated Nf1+/- 
(n=23). **P<0.05 for water-treated Nf1+/- versus apocynin-treated Nf1+/- (n=26). 
Analysis by one-way ANOVA with Tukey’s post hoc test. Error bars denote the 
mean ± S.E.M. For B and C, no statistical significance was observed for water-
treated WT versus apocynin-treated WT (n=24). (D) Severity index of AAAs of 
Ang II-infused WT and Nf1+/- mice treated with water (WT, n=14; Nf1+/-, n=23) or 
apocynin (WT, n=24; Nf1+/–, n=26). For B-D, saline-infused WT or Nf1+/- mice in 
either treatment group did not form aneurysms.  
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Figure 20. Apocynin prevents Ang II-induced AAA formation in Nf1+/- mice. 
(A) Representative photomicrographs of abdominal aortic cross-sections from 
water or apocynin-treated, Ang II-infused WT and Nf1+/- mice stained with H&E, 
(B) van Gieson for elastin or (C) anti-Mac-3 (arrowheads). Boxes specify area 
magnified in lower panel. Saline-infused WT and Nf1+/- mice treated with water or 
apocynin did not produce aneurysms. In B, arrowhead identifies fragmentation of 
elastic lamina and yellow staining identifies ECM. Scale bars: 50µm. 
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Figure 21 
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Figure 21. Apocynin reduces Ang II-induced superoxide formation in Nf1+/- mice. 
(A) Representative photomicrographs of abdominal aortic cross-sections from 
water or apocynin treated, Ang II-infused WT and Nf1+/- mice showing ROS 
identified by in situ DHE staining (red). Auto-fluorescence of murine tissue is 
visible (green). (B) Quantification of ethidium fluorescence for apocynin-treated, 
Ang II-infused WT and Nf1+/-.  
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DISCUSSION 
 
Cardiovascular disease, and specifically aneurysm formation, has 
hallmark pathologic features including macrophage infiltration and oxidative 
stress. NF1 patients and Nf1 heterozygous mice display evidence of chronic 
vascular inflammation characterized by an increase in circulating pro-
inflammatory monocytes (20, 22). Nf1 heterozygous mice displayed larger and 
more severe aneurysms compared to WT; however, overall comparisons 
between the aneurysms showed similar features of macrophage infiltration, 
elastic lamina degradation, MMP activity and superoxide formation. It is therefore 
likely that Nf1+/- aneurysm formation progresses via a similar pathogenesis to WT, 
and the increased incidence and severity is the result of increased circulating 
pro-inflammatory monocytes and increased oxidative stress produced from these 
monocytes and differentiated macrophages.  
Therefore, excessive vascular inflammation and oxidative stress within 
NF1 patients and mice provide a rational target for therapeutic intervention. 
Statins are efficacious in reducing inflammation and oxidative stress independent 
of their lipid lowering capacity in both human trials and animal models (175, 177, 
178). Specifically, statins reduce post-translational modification of proteins such 
as Ras and Rac, potentially resulting in reduced Ras activation and NAPDH 
activation, respectively, in aneurysm-inducing neurofibromin-deficient myeloid 
cells (151, 154). Additionally, statins have positive effects on the vascular 
endothelium within the first month of treatment, demonstrated by increased nitric 
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oxide synthesis and improved vascular homeostasis (160, 161). The safety 
profile is additionally important which makes them advantageous for use in 
pediatric patients, as evidenced by recent trials in NF1 children (179), which may 
be important since evidence of vascular inflammation was identified in 
adolescent NF1 patients (22).  
In the current study, simvastatin dramatically reduced Nf1+/- aneurysm 
formation with corresponding attenuation of MMP-9 activation and ROS 
production, lending strong evidence to the role of inflammation and oxidative 
stress in NF1 aneurysm development, as well as a potential therapeutic option 
for patients. Importantly, simvastatin was administered at a relatively low dose 
compared to other studies, which likely explains the absence of aneurysm 
attenuation in WT mice. These findings indicate NF1 patients and mice may be 
more susceptible to the positive effects of simvastatin at a lower dose than non-
NF1 patients, due to increases in both Ras activation and Rac activation of 
NOX2 in untreated patients. Based on our pre-clinical findings that low-dose 
statin treatment attenuates aneurysm formation and vasocclusive disease (20), it 
is possible that statins could be a viable therapeutic intervention in NF1 patients 
for the prevention and treatment of CVD.  
To further evaluate the biochemical mechanisms of NF1 aneurysm 
formation and identify another possible therapeutic for the treatment of NF1 CVD, 
Nf1 heterozygous mice were treated with the antioxidant and NOX2 inhibitor, 
apocynin. Treatment reduced aneurysm incidence to near WT levels while 
significantly attenuating MMP activity and superoxide formation. These results, 
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as well as increased oxidative damage in white blood cells of NF1 patients, 
strongly suggest ROS derived from monocytes and/or macrophages as the 
biochemical mechanism leading to NF1 aneurysm formation. Apocynin inhibition 
of NOX2 may also reduce the homing or inflammatory activity of neurofibromin-
deficient myeloid cells, similar to findings in a WT pain model (180).  
Together, these results indicate Nf1+/- aneurysmal disease progresses via 
a similar pathogenic mechanism to normal aneurysm development; however, due 
to the increases in inflammation and ROS, larger and more severe aneurysms 
are produced. Additionally, we provide pharmacologic evidence that aneurysm 
formation in Nf1+/- mice is significantly attenuated by daily low-dose 
administration of the HMG-CoA reductase inhibitor simvastatin, as well as the 
NOX2 inhibitor apocynin. Finally, these studies provide compelling pre-clinical 
evidence implicating simvastatin and apocynin as possible therapeutic 
interventions for both the prevention and treatment of NF1 cardiovascular 
disease. 
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